Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of liraglutide on gallbladder emptying: a randomised, placebo-controlled trial in adults with overweight or obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: The aims of the study were to investigate the effects of the GLP-1 receptor agonist liraglutide as add-on to metformin on insulin sensitivity (Si) and glucose effectiveness (Sg) in addition to its positive effects on beta-cell function in overweight/obese patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM).

MATERIAL AND METHODS: Design: A randomized, double-blind, placebo-controlled, cross-over trial in patients with stable CAD and newly diagnosed well-controlled T2DM. Patients were treated with liraglutide/metformin vs. placebo/metformin for a 12 + 12-week period with ≥2-weeks wash-out. First phase insulin secretion (AIRg), Si and Sg were estimated by the Bergman Minimal Model enabling calculation of beta-cell function; Disposition Index (DI)= AIRg x Si. Thirty patients of 41 randomized were available for paired analysis.

RESULTS: Baseline characteristics: HbA1c 47 mmol/mol (SD 6), BMI 31.6 kg/m(2) (SD 4.8), fasting plasma-glucose 6.9 mmol/l (IQR 6.1;7.4) and HOMA-IR 4.9 (IQR 3.0;7.5). Liraglutide treatment improved AIRg by 3-fold; 497 mU×l(-1)  × min (IQR 342;626, p < 0.0001) and DI by 1-fold; 766 (SD 824, p < 0.0001). Despite a significant weight loss of -2.7 kg (-6.7;-0.6) during liraglutide treatment we found no improvement in HOMA-IR, Si or Sg. Weight loss during liraglutide therapy did not cause a carry-over effect.

CONCLUSION: Liraglutide as add-on to metformin induces a clinical significant improvement in beta-cell function in overweight/obese high cardiovascular risk patients with newly diagnosed well-controlled T2DM and CAD. The effect of liraglutide on DI is mediated entirely by improved AIRg whereas the effects on Si and Sg are neutral.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism Online
Volume19
Issue number6
Pages (from-to)850-857
ISSN1463-1326
DOIs
Publication statusPublished - 1 Jun 2017

ID: 49799785